Download MendeleyDiscovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.
Sandanayaka, V., Mamat, B., Mishra, R.K., Winger, J., Krohn, M., Zhou, L.M., Keyvan, M., Enache, L., Sullins, D., Onua, E., Zhang, J., Halldorsdottir, G., Sigthorsdottir, H., Thorlaksdottir, A., Sigthorsson, G., Thorsteinnsdottir, M., Davies, D.R., Stewart, L.J., Zembower, D.E., Andresson, T., Kiselyov, A.S., Singh, J., Gurney, M.E.(2010) J Med Chem 53: 573-585
- PubMed: 19950900
- DOI: https://doi.org/10.1021/jm900838g
- Primary Citation of Related Structures:
3FH5, 3FH7, 3FH8, 3FHE, 3FTZ, 3FUL - PubMed Abstract:
Both in-house human genetic and literature data have converged on the identification of leukotriene 4 hydrolase (LTA(4)H) as a key target for the treatment of cardiovascular disease. We combined fragment-based crystallography screening with an iterative medicinal chemistry effort to optimize inhibitors of LTA(4)H. Ligand efficiency was followed throughout our structure-activity studies. As applied within the context of LTA(4)H inhibitor design, the chemistry team was able to design a potent compound 20 (DG-051) (K(d) = 26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke. The structural biology-chemistry interaction described in this paper provides a sound alternative to conventional screening techniques. This is the first example of a gene-to-clinic paradigm enabled by a fragment-based drug discovery effort.
Organizational Affiliation:
Medicinal Chemistry, deCODE Chemistry, Inc., 2501 Davey Road, Woodridge, Illinois 60517, USA.
